Skip to main content

Published locations for CML-CP: Imatinib discontinuation feasible in children with sustained DMR for at least 2 years

Primary tabs

  • View
  • Get Stamp Tags
  • Published Locations

Breadcrumb

  1. Home
  3. CML-CP: Imatinib discontinuation feasible in children with sustained DMR for at least 2 years

User login

  • Reset your password
  • /content/cml-cp-imatinib-discontinuation-feasible-children-sustained-dmr-least-2-years
  • /hematology-oncology/article/246648/cml/cml-cp-imatinib-discontinuation-feasible-children-sustained